Subjects from two additional COPD case-control studies were merged with the ECLIPSE subjects in the combined GWAS analysis and the GWAS meta-analysis [11]. COPD cases and control smokers were Caucasians recruited in Bergen, Norway [18], [19]. Cases were defined by GOLD stage 2 or greater COPD; smoking controls had normal lung function. Both cases and controls had smoking history of at least 2.5 pack-years. GWAS included 838 cases and 791 controls, genotyped using the Illumina HumanHap550 BeadChip [12].
